Hypertonic saline in patients with primary ciliary dyskinesia: on the road to evidence-based treatment for a rare lung disease

Editorial accompanying “A randomized controlled proof of concept study on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia” by Tamara Paff et al.

Full names, institution and country of all co-authors:

Claudia E. Kuehni (1, 2),
Myrofora Goutaki (1,2)
Helene E. Kobbernagel (3),

1) Institute of Social and Preventive Medicine, University of Bern, Switzerland.
   claudia.kuehni@ispm.unibe.ch, +41(0)31 631 35 07
2) Paediatric Respiratory Medicine, Children’s University Hospital of Bern, University of Bern, Switzerland
3) Danish Paediatric Pulmonary Service, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Instructions:

• 1780 words
• 1 Textbox
• 29 Refs
• No online appendix

Acknowledgements: CEK is a participant in the European Union’s Seventh Framework Programme under EG-GA No.35404 BESTCILIA: Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia. All authors participate in the network of COST Action BEAT-PCD: Better Experimental Approaches to Treat PCD (BM 1407); CEK and MG were members of the ERS PCD Taskforce for PCD Diagnostics (ERS TF-2014-04). The views expressed in this manuscript do not reflect official views of these collaborations. We thank Christopher Ritter for proofreading and editorial contributions.

Address for correspondence

Claudia E. Kuehni
Institute of Social and Preventive Medicine, University of Bern
Finkenhubelweg 11
CH-3012, Bern, Switzerland.
Phone: +41 (0)31 631 35 07, Fax: +41 (0)31 631 35 20,
e-mail: claudia.kuehni@ispm.unibe.ch
The study of Paff and collaborators, published on this year’s Rare Disease Day, describes the first randomised clinical trial of inhaled hypertonic saline on quality of life and other outcomes in patients with primary ciliary dyskinesia (PCD) [1]. Although results were negative, the study is a major step towards evidence-based treatment of PCD.

PCD—a rare lung disease

PCD is a rare inherited disease caused by abnormal ciliary structure and/or function [2,3]. PCD is heterogeneous: mutations in over 30 genes result in a variety of ultrastructural and functional deficits [4], and its clinical presentation varies broadly [5]. PCD mostly manifests with symptoms of the upper and lower airways, but can involve many other organs with ciliated cells. Its diagnostic work-up, summarised in the recent guideline from the European Respiratory Society (ERS) [4], is hampered by the lack of a diagnostic test that unambiguously confirms or excludes PCD. We currently must employ a combination of technically demanding tests that include measurement of nasal nitric oxide, high-speed video microscopy, transmission electron microscopy (EM), and in some cases genotyping and immunofluorescence of ciliary proteins. Prevalence has been estimated at around 1 in 10,000, [3,6] though it is higher in consanguineous communities [7].

An ERS taskforce in 26 countries studied diagnosis and management of PCD in paediatric centres. It found wide variability in prevalence—usually much less than 1/10,000 [6]. Care is decentralised and many centres follow only 1 to 5 patients. Treatment varies both between and within countries, and can involve airway clearance therapy, exercise, administering acute and prophylactic antibiotics, bronchodilators, inhaled corticosteroids, and the use of recombinant human deoxyribonuclease. Most studies had a mixed population of PCD and other respiratory patients, and PCD often was not diagnosed with state-of-the-art methods. The consensus statement of the taskforce concluded that it could not recommend extrapolating from cystic fibrosis (CF) to PCD, since the pathophysiology of these two disorders differs, and it reported a lack of good evidence for the effectiveness of any treatment. The taskforce also called for large, well-designed, randomised controlled trials that clearly describe patients [2].

What this study did

The Paff et al. [1] is a collaboration between paediatric and adult pulmonologists. In their randomised double-blind crossover trial, 22 patients received twice-daily inhalation of either hypertonic saline (HS, 7%) or isotonic saline (IS, 0.9%), and then after four weeks repeated the inhalation procedure with the other solution. Primary outcome was a change in health-related quality of life (the overall score of the St. George’s Respiratory Questionnaire, SGRQ). Secondary outcomes were SGRQ subscores, the Quality-of Life Questionnaire-Bronchiectasis (QOL-B), lower respiratory tract symptoms, exacerbations, spirometry, systemic and sputum inflammatory markers, adherence, and adverse events. The carefully designed study, reported according to CONSORT criteria, has many strengths:
- It is the first clinical trial to include only patients with confirmed PCD.
- The order of treatment was randomized and allocation was concealed from investigators, patients, and treating physicians throughout the study.
- The taste of the HS solution was masked (in both solutions) by quinine sulfate.
- Results were analysed taking intention-to-treat and per-protocol approaches.
- The target sample size (24 patients) was based on the minimal clinically important difference (MCID) of the main outcome (a 4-point reduction in SGRQ total score), and accounted for possible withdrawals.

What the study found
Patient recruitment was difficult. Of the 86 patients invited to participate, three did not meet the inclusion criteria and 61 declined to participate due to personal reasons, inconvenience, or their desire to not change their current medication.

Results were mostly negative. Although QoL (SGRQ total score) improved more after HS inhalations (-2.6 points) than after IS inhalations (-0.3 points), the difference neither reached the 4-point MCID nor was statistically significant. Also, results for most secondary endpoints were negative with the exception of the QOL-B Health Perception Scale and the LRTI visual analogue scale for chest pain. Given the number of comparisons (41), chance could explain these findings. Adverse events were more common after HS but were mild (throat irritation, cough, chest tightness).

How can we explain the negative findings? Hypertonic saline may not help patients with PCD, at least to a clinically significant extent. But there are alternative explanations.

- The active and control treatments might not have been sufficiently distinct: isotonic saline could also benefit patients by humidifying airway surface liquid [8], and quinine sulfate, the bitter compound used for taste-masking in both groups, has been reported to stimulate ciliary frequency and have bronchodilatory effects [9,10].
- HS might not have been administered in the most effective way. QoL in PCD is also influenced by ENT problems [11]. Administration of HS via a face mask instead of a mouthpiece might have been more effective. Combination with intense physiotherapy or an exercise program to facilitate expectoration of the liquefied sputum might have made inhalations more effective.
- The outcome measures used in the study were not very sensitive. The St. George’s Respiratory Questionnaire was designed for patients with asthma and COPD; it does not include symptoms typical for PCD such as chest congestion. This might explain why QOL-B, designed for bronchiectasis patients, indicated better outcomes. But even QOL-B excludes ENT symptoms. Future trials will benefit from the new PCD-specific instrument (QOL-PCD), which it is hoped will be more sensitive [12,13]. Also, spirometry (FVC, FEV1 and FEF 25-75) was used to measure lung function, but spirometry measures mainly proximal obstruction. Patients with PCD, like those with CF, primarily have peripheral airway obstruction that is picked up much better by gas washout techniques [14-16].
- Although the study nearly reached the target sample size, it was underpowered mainly because observed variability of the outcomes was larger than anticipated. The detailed data on the variability observed (online Table E5) will help the planning of future studies.

Improving treatment for other rare diseases: cystic fibrosis and paediatric cancers

The problems encountered in this study hamper evidence-based treatment, but are typical for research on rare diseases. Management of some rare diseases has progressed more than others.

Among pulmonary disorders, CF stands out. During recent decades we have seen major advances in standardisation of diagnostics and management of CF [17], early diagnosis and treatment thanks to newborn screening [18], centralised treatment in experienced clinics with multidisciplinary teams [19], development of disease-specific outcome measures [20], and randomised controlled trials [21]. Together, these efforts have fantastically improved long-term CF survival to a median age greater than 40 years in developed countries [22]. But why CF, and not also PCD? While CF is rare, it is more common than PCD, affecting 1 in 3000 persons. CF is diagnosed with simple and reliable diagnostic methods, and it has a severe disease course from early life, which leads to increased awareness. In PCD serious complications such as bronchiectasis develop mostly in adulthood when patients are dispersed among numerous adult specialists who each care for only one or two PCD patients in a lifetime. Finally, patient organisations have played a major role in advancing CF research, and CF patients seem to be more willing to participate in clinical studies (based upon personal experience seeing both PCD and CF patients in a large clinic in Copenhagen).
Perhaps the most successful precedent in clinical study of rare disease is childhood cancer. Although childhood cancers are rare, affected children have been systematically included in international clinical studies since the 1970s [23]. These are usually Phase 3 trials in which the control arm receives state-of-the-art therapy typically including a combination of several chemotherapeutic drugs, radiotherapy, and surgery. One or more experimental arms differ in one or more aspects by including new drugs or varying modes of applications of old drugs, or by stratifying patients into risk groups with different levels of treatment. A study usually includes patients with a specific type of cancer and paediatric oncologists strive to enter every patient into a study. When this is not possible, children are treated according to the control arm of the current study. The best arm in each study is then used as the control arm for a next-generation trial. Recruitment into these trials is high and a large majority of families give consent [24]. Successive studies since the 1960s have led to continuous improvement in treatment; survival rates have increased from 10% in the 1960s to over 85% [23]. Notably, almost all improvement has been obtained by combining common therapies in the most effective manner, rather than by using new drugs. While current studies still aim to optimize treatments, they pay increased attention to reducing acute and long-term treatment side effects. The first paediatric oncology trials were done in national networks, but current studies are usually international [23].

**How to move forward**

The RCT of Paff et al. is not a frustrating experience. It provides detailed clinical data for PCD patients, and helps us to design future studies:

1. **The pathophysiology in PCD is unique.** A treatment that works for CF or non-CF bronchiectasis [8,25] might not for PCD. We must conduct studies including only patients with state-of-the-art diagnoses of PCD [4].

2. **We must learn more about variability in outcome measures in patients with PCD.** This study's data and further observational data collected in international datasets such as the Provalf cohort planned as part of the COST Action BEAT-PCD [26], the international PCD (iPCD) cohort study [27], and the international PCD registry [28] will be important.

3. **We need more sensitive outcome measures such as disease-specific QoL instruments** (not yet available when this study was conducted) and sensitive lung function measurements [14,16].

4. **We should design interventions that account for the multisystem aspect of PCD.** A management strategy that benefits upper and lower airways or combines mucus liquidification and expectoration might be more effective.

5. **To improve recruitment we should organise multinational studies and include children** (who account for most diagnosed patients); simplify studies by reducing number of visits, time needed, and invasive measurements; embed studies in routine care; and promote an alliance between patients and doctors to advance knowledge and develop better PCD treatments.

An ongoing multicentre study that evaluates the efficacy and safety of azithromycin as maintenance therapy in PCD, as part of the EU FP7 project BESTCILIA, has many of these attributes, though it does suffer from recruitment difficulties [29].

To truly improve the evidence base for treatment of PCD and other rare lung diseases, we need major rethinking. We propose some key points (Textbox) borrowed and adapted from the standards of care developed by the European Society for Paediatric Oncology (SIOP) together with patients and parents [23,30]. We believe that adopting these points could lead to a significant improvement in care for patients with rare lung diseases such as PCD.
Proposed key elements for improving treatment of patients with rare lung diseases

(adapted from SIOP Europe’s proposed seven key elements for a national cancer strategy)

**International and national management plans**
Every country should have national guidelines that contain specific standards for age-appropriate treatment and care for children and adults with rare lung diseases. These should be based on international evidence-based guidelines, but account for local varying factors.

**Disease registration**
Every country should support prospective national and international registration and follow-up of children and adults with rare lung diseases.

**Access to specialists**
Defined referral pathways should exist so that every patient has access to innovative, age-appropriate treatment managed at a specialized treatment centre. Transition from paediatric to adult care centres should be established.

**Multidisciplinary teams**
Every child and adult with a rare lung disease should be treated by a multiprofessional team, which treats a sufficient number of patients with the same disease to maintain the necessary skills and participates in auditing and accreditation schemes.

**Standardised treatment**
Every patient diagnosed with a rare lung disease for which an observational or interventional clinical study is available should be entered into the relevant study at time of diagnosis. This will enable the patient to profit from the best available treatment. If formal participation in a study is not possible, patients still should be treated according to that study’s protocol whenever possible.

**Research**
A national strategy is needed to ensure support for investigator-led clinical and translational research, with the recognition that participation of patients in clinical trials is integral to delivery of best-practice care for people with a rare lung disease.

**Family support and role of patient’s organizations**
Parental and other family support is crucial to treatment outcome of persons with rare diseases. Patient organizations, too, are essential partners when developing and implementing health care policies.
References


